Showing results (471-480 of 10,436) with videos related to
Sort By:
Pageof 1,044
AIDS (London, England)|March 12, 2021
Plasma biomarker factors associated with neurodevelopmental outcomes in children with perinatal HIV infection and controlled viremiaSuad Kapetanovic, Mark J Giganti, Mark J Abzug, et al.AIDS (London, England)|March 12, 2021
Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxisThomas L Nickolas, Jonathan Barasch, Kenneth K Mugwanya, et al.AIDS (London, England)|December 6, 2021
TRIM22 genotype is not associated with markers of disease progression in children with HIV-1 infectionMichael T Boswell, Louis-Marie Yindom, Dan Hameiri-Bowen, et al.AIDS (London, England)|October 25, 2022
Functional analysis of the antigen binding sites on the MTB/HIV-1 peptide bispecific T-cell receptor complementarity determining region 3αChao-Ying Zhou, Rui-Ning Wang, Wen-Ting He, et al.AIDS (London, England)|September 29, 2022
Preliminary report on the provision of HIV care to war refugees with HIV who are migrating from Ukraine: data from the ECEE Network GroupJustyna D Kowalska, Nino Rukhadze, Lubomir Sojak, et al.AIDS (London, England)|September 9, 2022
A prospective study of clinical outcomes of HIV-associated and HIV-negative Kaposi sarcoma in UgandaWarren Phipps, Scott V Adams, Peter Mooka, et al.AIDS (London, England)|October 7, 2022
Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamideSean Dickson, Nico Gabriel, Inmaculada HernandezAIDS (London, England)|June 3, 2011
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combinationSusan M Schader, Susan P Colby-Germinario, Jordana R Schachter, et al.AIDS (London, England)|June 8, 2011
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovirAlana Brennan, Denise Evans, Mhairi Maskew, et al.AIDS (London, England)|May 4, 2011
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapsePablo Labarga, Pablo Barreiro, José A Mira, et al.Pageof 1,044